M&A and private equityAdvanced · ~50 minWorking draft · 11 sheets · 355 formulas

Kimberly-Clark and Kenvue merger model

Kimberly-Clark’s 2026 acquisition of Kenvue: shares, cash, synergies, leverage. Read a real stock-and-cash merger from its filings: price it at a fixed exchange ratio, fund the cash, rebuild earnings per share with and without the synergies, track leverage to the target, and say what the premium leaves for the buyer’s holders.

By Surojit Chakraverti, founder of L3VLUP and an investor running a long-short healthcare and technology equities strategy.

On this subject: kimberly-clark and kenvue merger model.Updated 20 November 2026

Who builds it, and for whatThe model an adviser, a credit analyst or a shareholder builds when a strategic buyer pays mostly in its own shares: the offer as a fixed exchange ratio and cash, the funding as the filings describe it, earnings per share against the buyer standalone, leverage against the stated target, and the synergy value against the premium. Built from the deal’s SEC filings, with every input they do not give labelled as an assumption.

Every sheet below, in your browser, with its outputs and checks

Starter workbook free with an account. Worked model: one a month with Plus, every one with Pro. Downloads

Inspect the workbook
All checks read zero100%
Every value, every sheet, as the workbook holds it.
ABCDEFGH
1Assumptions
2$m unless stated. Disclosed figures carry their source on the Sources sheet; the rest are illustrative inputs, labelled.
4DriverUnitFY2027EFY2028EFY2029EFY2030ENotes
5Scenario
6Scenario#11 = base, 2 = downside, 3 = upside. Base: Kimberly-Clark management’s view of Kenvue and the disclosed synergies. Downside: half the synergies, a year later. Upside: Kenvue management’s own projections and the disclosed synergies.
8The merger agreement (2 November 2025)
9Cash per Kenvue share$ per share3.50Disclosed: the Cash Consideration (8-K of 3 November 2025, Item 1.01).
10Exchange ratio, Kimberly-Clark shares per 1,000 Kenvue sharesshares146.25Disclosed: 0.14625 of a Kimberly-Clark share for each Kenvue share, fixed, with no collar (8-K of 3 November 2025, Item 1.01).
11Kimberly-Clark share price used to value the stock$ per share119.71Disclosed reference: the close on 31 October 2025, on which the announcement’s $21.01 and $48.7bn were struck (joint proxy, Background of the Mergers, p.72). The stock part floats with this price; the price at completion is not given in the documents read.
12Kenvue reference price for the premium$ per share14.37Disclosed: Kenvue’s close on 31 October 2025, after the acetaminophen reports (joint proxy, p.72). Other readings the proxy gives: the 90-day volume-weighted average of $18.24, and $20.54 on 28 August 2025, the day of the first proposal.
13Kenvue 90-day volume-weighted average price to 31 October 2025$ per share18.24Disclosed (joint proxy, K-C board’s reasons, p.77).
14Kenvue shares outstanding at signingm shares1,915.80Disclosed: 1,915.8 million at 30 October 2025, the figure in the merger agreement (joint proxy, pro forma note 4, p.181).
15Kenvue net debt at 28 September 2025$m7,834.0Disclosed: debt $8,973m less cash $1,139m (Kenvue 10-Q for the third quarter of 2025). The announcement’s enterprise value does not itemise its bridge.
16Enterprise value, as announced$m48,700.0Disclosed: approximately $48.7bn (joint press release, 3 November 2025).
17EV / LTM adjusted EBITDA, as announcedx14.3xDisclosed: approximately 14.3x, or 8.8x including the run-rate synergies (joint press release).
18EV / LTM adjusted EBITDA plus run-rate synergies, as announcedx8.8xDisclosed (joint press release).
20Completion (2 November 2026)
21Kimberly-Clark shares delivered to Kenvue holdersm shares281.06Disclosed: approximately 281,060,840 (Kimberly-Clark 8-K of 2 November 2026, Item 2.01). Converted equity awards are not counted.
22Kimberly-Clark shares outstanding before completionm shares332.60Disclosed: at 30 September 2026 (Kimberly-Clark 10-Q for the third quarter of 2026). For ownership.
23Kimberly-Clark diluted shares, standalonem shares333.70Disclosed: the diluted weighted average for the third quarter of 2026 (same 10-Q). Held flat: buybacks are not modelled, and the announcement limits them until leverage is back to about 2.0x.
25Funding the cash (October 2026)
265.100% notes due 2028$m750.0Disclosed (Kimberly-Clark 8-K of 29 October 2026, Item 1.01).
275.300% notes due 2029$m1,000.0
285.450% notes due 2031$m1,250.0
295.650% notes due 2034$m750.0
305.800% notes due 2036$m1,150.0
31Coupon, 2028 notes%5.1%
32Coupon, 2029 notes%5.3%
33Coupon, 2031 notes%5.5%
34Coupon, 2034 notes%5.7%
35Coupon, 2036 notes%5.8%
36New senior notes$m4,900.0$4.9bn, issued 29 October 2026 to fund the cash consideration and costs.
37Weighted coupon on the new notes%5.5%The forward-starting swaps settled at issue (10-Q, note 5) are left out.
38Commercial paper drawn at completion$m1,000.0Disclosed: approximately $1.0bn (Kimberly-Clark 10-Q for the third quarter of 2026, note 12).
39Rate on commercial paper%4.0%Illustrative. Not disclosed.
40Interest forgone on cash used%3.0%Illustrative.
41Transaction costs paid at completion$m309.0Disclosed estimates: Kimberly-Clark’s $259m of transaction expenses and $50m of retention bonuses at closing (joint proxy, pro forma notes 4f and 4g, p.183). Kenvue’s own costs are not disclosed.
43Balance sheets before completion
44Kimberly-Clark debt, 30 September 2026$m6,491.0Disclosed: $621m within one year and $5,870m long-term (10-Q for the third quarter of 2026).
45Kimberly-Clark cash, 30 September 2026$m1,874.0Disclosed (same 10-Q). Includes the IFP joint venture proceeds of July 2026.
46Kenvue debt, 27 September 2026$m8,206.0Disclosed (Kenvue 10-Q for the third quarter of 2026). Assumed: $6.4bn of Kenvue’s notes were exchanged for Kimberly-Clark notes on 4 November 2026, and about $0.6bn stayed outstanding.
47Kenvue cash, 27 September 2026$m1,039.0Disclosed (same 10-Q).
48Kimberly-Clark interest expense, standalone$m256.0FY2025 as reported (10-K), held flat. Illustrative as a forecast.
49Kenvue interest expense, standalone$m430.0FY2025 as reported (Kenvue 10-K), held flat. Illustrative as a forecast.
50Rate on the change in net debt after completion%5.0%Illustrative. Applied to net debt above or below the level at completion.
52Tax and other earnings items
53Kimberly-Clark tax rate, applied to the deal adjustments%22.8%Disclosed: the FY2025 adjusted effective tax rate (10-K). Illustrative as a forecast.
54Kenvue tax rate, standalone%26.5%Derived: FY2025 tax of $529m on pre-tax income of $1,999m (Kenvue 10-K). Illustrative as a forecast.
55Kimberly-Clark depreciation and amortisation, % of revenue%4.9%Derived: FY2025 $805m on revenue of $16,447m (10-K). Illustrative as a forecast.
56Kenvue depreciation, % of revenue%2.0%Derived: FY2025 depreciation and amortisation of $557m less amortisation of $257m, on revenue of $15,124m (Kenvue 10-K). Kenvue’s own amortisation is replaced by the purchase accounting below.
57Kimberly-Clark share of net income of equity companies$m196.0FY2025 as reported (10-K), held flat. The IFP joint venture’s share from July 2026 is not added.
58Amortisation of acquired intangibles, a year$m335.0Disclosed, preliminary: $136m on $1,352m of brands over 10 years and $199m on $2,992m of customer relationships over 15 years; $30,275m of brands are indefinite-lived and not amortised (joint proxy, pro forma notes 4c and 4bb, pp.183 to 185).
59Purchase accounting amortisation in earnings per share#11 = included, 0 = excluded. Whether the combined company’s adjusted earnings exclude it is not disclosed.
60Dividend per share, combined company$ per share5.12Disclosed rate: $1.28 a quarter in 2026 (10-Q), annualised and held flat. Illustrative as a forecast. Paid on every share after completion.
62Kimberly-Clark standalone projections (Kimberly-Clark management)
63Revenue$m17,427.017,931.018,459.019,013.0Disclosed (joint proxy, K-C standalone projections, pp.118 to 119).
64Adjusted EBITDA$m4,003.04,325.04,452.04,586.0Disclosed (same table).
65Unlevered free cash flow$m1,933.02,299.02,389.02,494.0Disclosed (same table).
67Kenvue projections, two views
68Revenue, as adjusted by Kimberly-Clark management$m15,678.016,133.016,694.017,291.0Disclosed (joint proxy, K-C management adjusted Kenvue projections, p.120): slower growth, more marketing and R&D, savings later.
69Adjusted EBITDA, as adjusted by Kimberly-Clark management$m3,414.03,547.03,816.04,077.0
70Unlevered free cash flow, as adjusted by Kimberly-Clark management$m2,186.02,326.02,533.02,633.0
71Revenue, Kenvue management$m15,913.016,500.017,154.017,847.0Disclosed (joint proxy, Kenvue standalone projections, pp.119 to 120).
72Adjusted EBITDA, Kenvue management$m3,852.04,198.04,576.04,911.0
73Unlevered free cash flow, Kenvue management$m2,515.02,815.03,103.03,256.0
74Revenue, selected scenario$m15,678.016,133.016,694.017,291.0
75Adjusted EBITDA, selected scenario$m3,414.03,547.03,816.04,077.0
76Unlevered free cash flow, selected scenario$m2,186.02,326.02,533.02,633.0
78Synergies (joint proxy, synergy projections, p.121)
79Run-rate cost synergies, EBITDA$m1,893.0Disclosed: $1,893m a year from the third year (the announcement: approximately $1.9bn, in three years).
80Run-rate growth synergies, EBITDA, net of reinvestment$m216.0Disclosed: $216m a year from the fourth year (the announcement: about $500m of profit from revenue synergies less about $300m reinvested).
81Cost synergies, % of run-rate, base and upside%40.0%80.0%100.0%100.0%Disclosed profile: $757m, $1,514m, then $1,893m. Read as years after completion, a choice of this page.
82Cost synergies, % of run-rate, downside%0.0%40.0%80.0%100.0%Illustrative: the disclosed profile a year later.
83Cost synergies, % of run-rate, selected scenario%40.0%80.0%100.0%100.0%
84Growth synergies, % of run-rate, base and upside%25.0%50.0%75.0%100.0%Disclosed profile: $54m, $108m, $162m, then $216m.
85Growth synergies, % of run-rate, downside%0.0%25.0%50.0%75.0%Illustrative: the disclosed profile a year later.
86Growth synergies, % of run-rate, selected scenario%25.0%50.0%75.0%100.0%
87Synergies realised, % of disclosed, base and upside%100.0%Illustrative. The disclosed estimates in full.
88Synergies realised, % of disclosed, downside%50.0%Illustrative.
89Synergies realised, selected scenario%100.0%
90Cash cost to achieve, % of run-rate cost synergies%65.0%65.0%0.0%0.0%Disclosed: about 65% of run-rate cost synergies in each of the first two years, about $1,230m a year (joint proxy, pp.121 to 122); the announcement: $2.5bn in the first two years. Spent whether or not the synergies arrive.
91Integration capital spending$m1,400.0Disclosed: about $1.4bn through 2029 under the Kenvue Integration Program (8-K of 2 November 2026, Item 2.05).
92Integration capital spending, % by year%40.0%40.0%20.0%0.0%Illustrative. The timing is not disclosed.
93Multiple put on the run-rate synergies, EV / EBITDAx10.0xIllustrative. For scale: the advisers’ peer tables put Kenvue at 9.9x and Kimberly-Clark at 11.2x 2026 EBITDA (joint proxy, Centerview’s analysis, p.106).
95Litigation (a what-if, not an estimate)
96Litigation amount to test, after tax$m-Illustrative control, nil by default. Kenvue says it cannot estimate the likelihood or size of liability for the acetaminophen or talc claims (10-Q for the third quarter of 2026, note 13). Paid in FY2027E and funded with debt.
97Net leverage targetx2.0xDisclosed: approximately 2.0x net debt to EBITDA within 24 months of completion (investor presentation, 3 November 2025).

Select a cell to see its row, its schedule and the type of cell. Font colours: blue for inputs, black for formulas, green for links to other sheets. Scroll sideways to see every period.

Download

Kimberly-Clark and Kenvue merger model: the workbook

An Excel workbook with working formulas, no macros and no external links: the same model you can work with on this page.

  1. Browse without an accountPreview every model online, sheet by sheet, with its outputs and checks.
  2. Free accountWork with every model online: change the inputs, switch the case, see every formula. And every starter workbook, with its key schedules left blank to build.
  3. L3VLUP Plus$4.99/monthEverything in Free, and one worked model each billing month as an Excel file: every schedule built, formulas live, checks at zero, yours to keep.
  4. L3VLUP Pro$25/monthEverything in Plus, every worked model in the library, and the Pro applications.
The worked model
11 sheets and 355 live formulas, all 10 schedules built and linked, every check reading zero. Change an input in Excel and the whole model moves.
The starter
The same inputs and layout with the pro forma EPS: accretion and dilution left blank for you to build, each blank cell marked. The worked model is its answer.

What the base case says

Offer value per Kenvue share
21.01
Kimberly-Clark holders’ ownership
54.2%
Accretion / (dilution), FY2027E
0.4%
Accretion / (dilution), FY2028E
10.5%
Net debt / EBITDA, FY2028E
2.0x
Left for Kimberly-Clark’s holders
$2,561.0m

Read from the workbook as served, every input at its default. Periods: FY2027E, FY2028E, FY2029E, FY2030E. Built from the deal’s SEC filings, cited on the Sources sheet: the merger agreement and announcement, the joint proxy statement/prospectus with both companies’ projections and the synergy projections, the financing and completion reports, and both companies’ annual and quarterly reports. The rates the filings do not give, the timing read into the synergy profile, the multiple put on the synergies and any litigation amount are illustrative inputs, labelled, and move with whatever you type in.

What changes the answer

Every figure below is the workbook recalculated by its own formulas: the cases it carries, each key assumption moved a tenth either way, and the sensitivity grids from its own sheets. Nothing is estimated outside the model.

The cases, side by side

The scenario switch on the Assumptions sheet, set to each option in turn. Every check in the workbook reads zero in every case.

OutputBaseas shippedDownsideUpside
Offer value per Kenvue share21.0121.0121.01
Kimberly-Clark holders’ ownership54.2%54.2%54.2%
Accretion / (dilution), FY2027E0.4%-13.6%-14.0 pts7.6%+7.1 pts
Accretion / (dilution), FY2028E10.5%-9.1%-19.7 pts20.5%+9.9 pts
Net debt / EBITDA, FY2028E2.0x2.5x+0.5x1.8x-0.2x
Left for Kimberly-Clark’s holders$2,561.0m$-3,154.3m-$5,715.3m$2,561.0m
What each case assumes
Revenue, selected scenario15,678.015,678.015,913.0
Adjusted EBITDA, selected scenario3,414.03,414.03,852.0
Unlevered free cash flow, selected scenario2,186.02,186.02,515.0
Cost synergies, % of run-rate, selected scenario40.0%0.0%40.0%
Growth synergies, % of run-rate, selected scenario25.0%0.0%25.0%
Synergies realised, selected scenario100.0%50.0%100.0%

The first period of each assumption row the switch sets directly, in the order of the columns above.

What moves accretion or dilution most

Accretion / (dilution), FY2028E is 10.5% in the base case. Each bar moves one assumption 10% below and 10% above its own value, with everything else held, and shows where the output lands.

  • Adjusted EBITDA (kimberly-clark standalone projections)

    10% lower: 18.6%10% higher: 4.3%

  • Kimberly-Clark shares delivered to Kenvue holders

    10% lower: 16.3%10% higher: 5.3%

  • Adjusted EBITDA (kenvue projections)

    10% lower: 5.2%10% higher: 15.9%

  • Kimberly-Clark diluted shares

    10% lower: 5.3%10% higher: 15.2%

  • Synergies realised (synergies)

    10% lower: 7.9%10% higher: 13.2%

  • Cost synergies (synergies)

    10% lower: 8.1%10% higher: 13.0%

Assumption 10% lowerAssumption 10% higherBase case, 10.5%

The sensitivity grids, as heatmaps

Accretion / (dilution): synergy realisation by year

Accretion / (dilution) (%), by synergies realised, % of disclosed down and year across. From the Sensitivity sheet.
Synergies realised, % of disclosed ↓ / Year →FY2027EFY2028EFY2029EFY2030E
50.0%-6.6%-2.2%3.9%8.1%
75.0%-3.1%4.2%11.8%15.9%
100.0%0.4%10.5%19.6%23.7%
125.0%3.9%16.9%27.5%31.6%
150.0%7.4%23.3%35.4%39.4%
Below zeroAbove zero

Value left for Kimberly-Clark’s holders ($m): synergy multiple by realisation

Left for Kimberly-Clark’s holders ($m), by multiple on run-rate synergies down and synergies realised, % of disclosed across. From the Sensitivity sheet.
Multiple on run-rate synergies ↓ / Synergies realised, % of disclosed →50.0%75.0%100.0%125.0%150.0%
6.0x(5,440.4)(3,725.8)(2,011.2)(296.6)1,418.0
8.0x(4,297.4)(2,011.2)274.92,561.04,847.1
10.0x(3,154.3)(296.6)2,561.05,418.78,276.3
12.0x(2,011.2)1,418.04,847.18,276.311,705.5
14.0x(868.2)3,132.57,133.311,134.015,134.7
Below zeroAbove zeroThe base case, as the workbook ships

Presenting these figures? In Deck Studio a slide can carry any output above, with the case and the cell printed as its source.Open Deck Studio

What this model is

A transaction model of Kimberly-Clark’s acquisition of Kenvue: $3.50 in cash and 0.14625 of a Kimberly-Clark share for each Kenvue share, announced on 3 November 2025 and completed on 2 November 2026.

It prices the offer as the announcement did, issues the shares the completion report gives, funds the cash with the notes, commercial paper and cash the filings describe, and runs both companies’ disclosed projections with the disclosed synergies through FY2030E: earnings per share against Kimberly-Clark standalone, net debt against the 2.0x target, and the synergy value against the premium.

Uses: reading a stock-and-cash merger from its filings; seeing how much of the earnings case and the value case rests on the synergies; and testing what a lower realisation, a different view of Kenvue or a litigation amount would do.

Seats: Investment banking, Equity research and hedge funds, Private equity.

Careers that do this work: investment banking, private equity, growth equity, corp dev / m&a, venture capital.

How the schedules connect

Every row in the workbook is tagged with the schedule it belongs to; the inspector above shows the tag when you click a row. These are the schedules this model is made of and where each one lives.

Purchase price and consideration

Offer, premium, mix, new shares, exchange ratio

Assumptions, rows 9–18 · Assumptions, rows 21–23 · Offer & Ownership, rows 5–9 · Offer & Ownership, rows 18–26

Enterprise value to equity value

Debt off, cash on, per share

Assumptions, rows 96–97 · Offer & Ownership, rows 12–15 · Value, rows 11–18

Contribution analysis

What each side brings against what it owns

Offer & Ownership, rows 29–31

Sources and uses

What the deal costs and who funds it

Assumptions, rows 26–41 · Sources & Uses, rows 5–8 · Sources & Uses, rows 11–17

Debt schedule

Tranches, interest, amortisation and the sweep

Assumptions, rows 44–50 · Sources & Uses, rows 20–24 · Pro Forma EPS, rows 21–22 · Leverage, rows 6–12 · Leverage, rows 15–17

Tax

Tax on profit, and tax on operating profit

Assumptions, rows 53–57 · Assumptions, row 60 · Pro Forma EPS, row 25

Synergies

Run-rate, phase-in, after tax

Assumptions, rows 79–93 · Synergies, rows 6–11 · Synergies, rows 14–15 · Pro Forma EPS, row 20 · Pro Forma EPS, rows 36–41 · Value, rows 5–8 · Value, rows 21–24

Purchase accounting

The write-up that amortises

Assumptions, rows 58–59 · Pro Forma EPS, row 23

Pro forma EPS: accretion and dilution

Standalone to pro forma, per share

Assumptions, rows 63–65 · Assumptions, rows 68–76 · Pro Forma EPS, rows 6–11 · Pro Forma EPS, rows 14–17 · Pro Forma EPS, rows 24–26 · Pro Forma EPS, rows 29–33 · Pro Forma EPS, rows 44–48

Sensitivity tables

Two assumptions at once, without a data table

Sensitivity, rows 5–6 · Sensitivity, rows 9–14 · Sensitivity, rows 17–25

What you should be able to explain

  • Why a fixed exchange ratio fixes the number of new shares and leaves the value of the offer floating with the buyer’s price, and what that does to the premium the target’s holders receive.
  • How accretion is built: each company’s standalone earnings, the synergies, the interest on the funding and the purchase accounting, over a share count that grows by the shares issued.
  • Why accretion is not value: a deal can lift earnings per share in its second year and still leave the buyer’s holders little once the premium is set against what the synergies are worth.
  • How the holders of a stock deal share the synergies: the target’s holders keep the premium and their part of what the synergies add beyond it, the buyer’s holders the rest, by ownership.
  • How a litigation risk the filings cannot size is handled fairly: what the documents disclose, a material adverse effect definition that leaves it with the buyer, and a what-if amount rather than a forecast.

What a reviewer looks for

  • Quoting the $48.7bn enterprise value as the cash paid. More than 80% of the consideration was Kimberly-Clark shares; the cash was about $6.7bn.
  • Measuring the premium on one price only. On Kenvue’s close of 31 October 2025 it is 46.2%; on the 90-day average it is about 15%, because the shares had fallen after the acetaminophen reports.
  • Counting the synergies at their run-rate from the first year. The disclosed profile reaches the cost run-rate in the third year, and the $2.5bn of cost to achieve falls in the first two.
  • Reading accretion in the second year as proof of value. Without the synergies the deal dilutes Kimberly-Clark’s earnings per share in every year of the base case.
  • Treating the litigation as a number the filings give. Kenvue says it cannot estimate the likelihood or size of the claims; any amount in the model is a what-if you choose.

Conventions this workbook uses

Stated on the cover sheet too. A model is only as trustworthy as the decisions it tells you it made.

  • Disclosed figures are inputs with their source on the Sources sheet. Inputs the filings do not give are labelled illustrative in their notes: the rate on commercial paper and on any change in net debt, the timing of integration capital, the dividend held flat, the multiple put on the synergies, the downside case and the litigation amount.
  • The offer is fixed in shares and cash: 0.14625 of a Kimberly-Clark share and $3.50 for each Kenvue share. The number of new shares is the 281.1 million the completion report gives; their value depends on the Kimberly-Clark price chosen, by default $119.71, the close on which the announcement was struck.
  • FY2027E to FY2030E are the first four full years after completion. Both companies’ projections are the joint proxy’s, by fiscal year. The synergy projections’ profile is read as years after completion; the joint proxy tables them from fiscal 2026E on a completion not later than the second half of 2026.
  • Earnings per share are adjusted: the cash cost to achieve the synergies is kept out of earnings and counted in cash and leverage. Amortisation of the acquired intangibles is included unless the Assumptions sheet excludes it. Kenvue’s own past amortisation is replaced by it.
  • Standalone earnings are rebuilt from each projection’s adjusted EBITDA with depreciation, interest and tax at their FY2025 levels. Converted equity awards and buybacks are not modelled; the share count is held flat.
  • Kenvue’s debt is assumed, so it is in combined net debt but not in sources and uses. The notes carry their coupons; commercial paper and cash used carry illustrative rates; interest on net debt above or below the level at completion is charged at an illustrative marginal rate.
  • The value split works in market value at the prices chosen: net synergy value less the premium is what the merger adds for the two sets of holders together, and each keeps a share by its ownership of the combined company. Kenvue’s holders also keep the premium. Each standalone business is taken at its market price on the reference date, so a different view of Kenvue’s plan moves earnings and leverage, not the value split.
  • The litigation control is an amount you set, nil by default, paid in FY2027E and funded with debt. It is a what-if: the filings give no estimate, and Kenvue says it cannot make one.

Build it yourself

The starter workbook

The earnings per share build has been cleared: both companies’ standalone net income, the deal adjustments, pro forma net income and shares, accretion, the synergies a year needs for no dilution and the bridge from standalone to pro forma. Rebuild them from the Assumptions, the Synergies and the Sources & Uses sheets. The Checks sheet shows when the bridge and the accretion grid tie to your result.

Blanks: Pro forma EPS: accretion and dilution. Download it beside the worked model.

Finished? Audit a model you built for errors, hardcodes and checks that do not tie, in your browser.

The path around this model

Understand it, drill it, read the build, then apply it to a real company.

Vocabulary: Merger Model, Accretion / Dilution, Synergies, Control Premium, Purchase Price Allocation (PPA), Exchange Offer, Break Fee, Fairness Opinion, Net Debt.

Questions about this model

How much of this model is disclosed and how much is assumed?

Disclosed: the cash and the exchange ratio, the prices the announcement used, the share counts at signing and completion, the notes and commercial paper that funded the cash, both balance sheets, both companies’ projections to 2030 (Kenvue in two versions, its own and Kimberly-Clark’s adjusted one), the synergy projections and their cost to achieve, the preliminary purchase accounting and the leverage target. Assumed, and labelled: the rates on commercial paper and on later changes in net debt, depreciation, interest and tax held at their 2025 levels, the dividend held flat, the timing of the integration capital, the downside case, the multiple put on the synergies and any litigation amount.

Is the deal accretive?

In the base case, on the page’s assumptions, earnings per share are roughly unchanged in FY2027E and about 10.5% higher in FY2028E, as the synergies build. Without the synergies the deal dilutes earnings per share in every year, so the answer rests on them. The announcement said only that it expected the deal to be accretive to adjusted earnings per share by year 2. These are conditional figures, not the combined company’s results.

What does the litigation control do?

It lets you test an amount, nil by default. The amount is paid in FY2027E, funded with debt, adds to net debt and interest and comes off the value left after the premium. The filings disclose the claims (the acetaminophen cases remanded by the Second Circuit in July 2026, the Texas case under appeal, and talc claims outside the United States and Canada that Kenvue keeps), but Kenvue says it cannot estimate the likelihood or size of any liability, so the model carries no estimate of its own.

Why are there two versions of Kenvue’s projections?

Because the joint proxy discloses both. Kenvue’s management prepared its own plan; Kimberly-Clark’s management adjusted it for slower growth, more marketing and research spending and later savings, and that version is what Kimberly-Clark’s advisers used. The base case uses Kimberly-Clark’s version; the upside uses Kenvue’s own.

Related models

What assumption would you challenge?

Every model rests on a few judgements. Ask how one works, or say which input you would set differently and why.

Ask about this model

No questions yet. Ask the first.

All discussions · Community rules

Share your result 📊

𝕏in💬🤖

Instagram and TikTok have no desktop share link, so copy the caption and paste it into the app.